New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 4, 2012
01:43 EDTVRX, GILD, ABTVertex Pharmaceuticals offers investors few catalysts, Barron's says
Vertex Pharmaceuticals (VRX) was once a Wall Street darling, but sales of its blockbuster hepatitis C drug, Incivek, are falling. And as Incivek sales keep falling, many worry that Vertex may start losing money next year. Q3 results disappointed investors. And shares sank Friday, as Goldman Sachs analyst Terence Flynn downgraded the stock to a Sell. The worry is that experimental cystic fibrosis drugs now in development may not prove to be potent enough to help patients. Also, Gilead Sciences (GILD) and Abbott Laboratories (ABT) have rival hepatitis C drugs in phase three trials, which Vertex won't start until 2014. Barron's contends that Vertex faces challenges that make the stock unattractive even at a marked-down price. Reference Link
News For VRX;ABT;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 24, 2015
13:24 EDTVRXContact lens manufacturers accused of price-fixing, Bloomberg says
Subscribe for More Information
08:00 EDTGILDGilead shares should be bought on weakness, says Bernstein
Subscribe for More Information
March 23, 2015
16:01 EDTGILDOptions Update; March 23, 2015
iPath S&P 500 VIX Short-Term Futures down 48c to 25.24 Option volume leaders: AAPL TSLA TWTR GILD CELG FB TSLA AMZN TEVA PBR according to Track Data.
11:45 EDTGILDGilead defended after slide following death of Hep C patient on heart drug
Subscribe for More Information
11:32 EDTGILDStocks with call strike movement; GILD CELG
Gilead (GILD) August 115 call option implied volatility increased 5% to 27, Celgene (CELG) July 140 call option implied volatility increased 3% to 28 according to IVolatility.
09:37 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AUY SLB PFE MCP CELG VRTX SHPG GILD LOGI TSLA TASR NFLX SCTY WFM
09:03 EDTABTFiserv says Abbott employee credit union expands partnership
Subscribe for More Information
08:44 EDTGILDGilead volatility low into FDA hepatitis C drug warning
Subscribe for More Information
08:23 EDTGILDGilead weakness a buying opportunity, says RW Baird
Subscribe for More Information
07:51 EDTVRXValeant price target raised to $240 from $185 at Susquehanna
Susquehanna raised its price target on Valeant to $240 from $185 to reflect the addition of durable assets and the improved growth trajectory its recent deals brings to its U.S. business. Susquehanna reiterated its Positive rating on Valeant shares.
07:40 EDTGILDGilead weakness on FDA warning would be buying opportunity, says Wells Fargo
Subscribe for More Information
07:17 EDTVRXAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
06:08 EDTGILDGilead implied volatility of 23 at lower end of index mean range
Subscribe for More Information
March 22, 2015
15:05 EDTGILDGilead warns after hepatitis C patient taking heart drug dies, Bloomberg says
Gilead said in an e-mailed drug warning to health-care providers on Friday that nine patients taking its hepatitis C drugs Harvoni or Sovaldi along with the heart treatment amiodarone developed abnormally slow heartbeats and one died of cardiac arrest, says Bloomberg. Reference Link
March 20, 2015
16:33 EDTVRXStocks end week higher after market reads Fed statement as dovish
Subscribe for More Information
16:00 EDTGILDOptions Update; March 20, 2015
Subscribe for More Information
15:02 EDTGILDAcelRx names Howard Rosen as interim CEO
AcelRx Pharmaceuticals (ACRX) announced the appointment of Howard Rosen as interim CEO of AcelRx, effective April 1. Rosen is a technically trained executive with over 25 years of success growing start-up and mid-size biopharmaceutical companies. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences (GILD) and ALZA Corporation. Rosen has served on the Board of Directors of AcelRx since 2008 and currently serves on the Board of Directors of Alcobra and several private biopharmaceutical companies.
March 19, 2015
16:01 EDTGILDOptions Update; March 19, 2015
Subscribe for More Information
09:08 EDTGILDNew Gilead HIV drug likely to be approved in mid-2015, says Argus
Subscribe for More Information
March 18, 2015
05:45 EDTVRXSalix downgraded to Hold from Buy at Jefferies
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use